Menu
Search Close

Products

Cancer vaccine: SCIB1

Scancell’s first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials.

SCIB1 is a plasmid DNA which encodes a human antibody molecule engineered to express two cytotoxic T cell epitopes derived from the melanoma antigens Tyrosinase-Related Protein 2 (TRP2) and gp100 plus two helper T cell epitopes. Following immunisation, the engineered antibody is expressed and taken up by dendritic cells, resulting in the development of immune responses against tumour cells expressing the TRP2 and gp100 antigens. The major advantage of the Immunobody® technology is that the Fc component of the engineered antibody will be recognised by the high affinity CD64 receptor present on dendritic cells, leading to a significant enhancement of both the frequency and avidity of the T cell immune response. The induction of high avidity T cells against TRP-2 and gp100 destroys both primary and metastatic tumours, leading to longer progression free survival.

Phase I/II clinical trial of SCIB1

Scancell is conducting  a Phase I/II clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial is being carried out  at clinical sites in Nottingham, Manchester, Guildford, Leeds and Southampton. .

The trial is an open label, non-randomised study to determine the safety and tolerability of four doses of SCIB1 administered intramuscularly using an electroporation device (TDS-IM, manufactured by Ichor Medical Systems, USA). The study will also assess immune effects and anti-tumour activity in patients with melanoma. The trial is being conducted in patients with both unresected and resected disease.

Patients with Stage III or Stage IV melanoma  received up to five doses of the SCIB1 vaccine over a 6 month period.  In addition some  patients  are being given long term treatment every 3-6 months for up to 5 years. The  results to date have been highly encouraging.

All 20  patients with resected tumours are still alive and only five  have progressed. This compares very favourably with data from historical controls.

Further information on the study can be obtained at:

Melanoma patients are advised to consult their doctor for advice regarding their treatment.

Scientific Papers

PIVAC-15 

PIVAC-15 Programme


PIVAC SCIB2 Poster

Wei Xue, Rachael Metheringham, Victoria Brentville, Katherine Cook, Peter Symonds, Ian Daniel and Lindy Durrant


PIVAC SCIB1 resected disease

L.G. Durrant, C.Ottensmeier, C. Mulatero, P.Lorigan, R.Plummer, R.Metheringham, V.Brentville, L.Machado, I.Daniels, D.Hannaman & P.M.Patel


PIVAC SCIB1 plus checkpoint inhibition 

Wei Xue, Victoria Brentville, Rachael Metheringham, Katherine Cook, Peter, Symonds, Ian Daniel, and Lindy Durrant


PIVAC Moditope poster 2

V.Brentville, W.Xue, P.Symonds, K.Cook, B.Gunn, R.Metheringham and L.G. Durrant


PIVAC Moditope poster 1

Katherine Cook, Ian Daniels, Victoria Brentville, Rachael Metheringham, Wei Xue, Peter Symonds, Tracy Pitt, Mohamed Gijon and Lindy Durrant


Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4 T-Cell–Mediated Antitumor Immunity

Victoria A. Brentville, Rachael L. Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Katherine Cook, Wei Xue, and Lindy G. Durrant


ASCO Poster June 2015

P.M Patel, C Ottensmeier, C Mulatero, P Lorigan, R Plummer, M Cunnell, R Metheringham, V Brentville, L Machado, I Daniels, D Hannaman, L.G Durrant


AACR Moditope® poster April 2015 

Victoria A Brentville, Rachael L Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Wei Xue, Lindy G Durrant


High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
Victoria A. Brentville, Rachael L. Metheringham, Barbara Gun and Lindy G. Durrant


Using monoclonal antibodies to stimulate antitumour cellular immunity
Lindy Durrant, Victoria Pudney and Ian Spendlove

ASCO poster June 2014
P.M Patel, L.G Durrant, C. Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, M. Cunnell, R. Metheringham, V. Brentville, L. Machado, I. Daniels and D. Hannaman


Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses
Lindy Durrant, Victoria Pudney, Ian Spendlove and Rachel Metheringham


DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8 T cells
Victoria A. Pudney, Rachael L. Metheringham, Barbara Gunn, Ian Spendlove, Judith M. Ramage and Lindy G. Durrant


Antibodies designed as effective cancer vaccines
R.L. Metheringham, V.A. Pudney, B. Gunn, M. Towey, I. Spendlove and L.G. Durrant


Webcasts, Interviews and Media Coverage

Scancell raises £5mln in 'most successful round they've ever had' - CEO Richard Goodfellow

Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP) talks through with Proactive Investors their £5mln raise to fund clinical work on their pipeline of cancer immune-therapies.

Fri, 12 May 2017 07:57:00

Scancell boss 'very excited' about collaboration deal with leading US lung cancer foundation

Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.

CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.

Wed, 01 Feb 2017 09:53:00

Scancell poised for “significant” year with its immuno-oncology portfolio

"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

Tue, 11 Jul 2017 12:30:00